Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6229 in healthy subjects
NCT07285603Phase 1Completed
- Sponsor
- Matisse Pharmaceuticals
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of isupartob sodium in sepsis, sponsored by Matisse Pharmaceuticals. Primary endpoints: Incidence and type of Adverse Events, Change in electrocardiograms from baseline and 11 more. Started Nov 2024; status: completed.
02
Drugs
isupartob sodium
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07285603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07285603.